At that point, assuming we like the way its coming together, we negotiate a pre-defined exitpath for a possible investment: upon successful completion of XYZ clinical study, the Pharma will buyout the asset-centric entity in an upfront plus milestones type transaction.
But no-one knows for sure what the consequences of a Greek exit would be, and whether it would prove to be significantly more expensive than the current path.